The Brewer Group, a global investment advisory firm, has announced a strategic partnership with ViaDerma, a developer of advanced topical pharmaceuticals. The partnership will see The Brewer Group expand ViaDerma's business development, marketing and distribution efforts domestically and abroad to grow demand for ViaDerma's patent-pending rapid delivery system. This system allows for rapid transdermal transfer and immediate relief of active ingredients. The Brewer Group will utilize its international presence and relationships to connect ViaDerma with pharmaceutical companies and distribution channels worldwide. The CEOs of both companies commented that this partnership will help bring ViaDerma's revolutionary delivery system to more audiences by combining their marketing expertise with ViaDerma's innovative technologies.

1. THE BREWER GROUP ANNOUNCES STRATEGIC PARTNERSHIP WITH VIADERMA, INC.
Collaboration will help expand the domestic and international demand for ViaDerma’s cutting-edge
pharmaceutical rapid delivery system
MINNEAPOLIS, MINNESOTA AND BEVERLY HILLS, CALIFORNIA, JULY 31, 2014 - ViaDerma, Inc. (VDRM), a
developer of advanced topical pharmaceuticals, and The Brewer Group, Inc. (TBG), a diversified global
investment advisory firm, today announced a new strategic partnership. TBG will expand ViaDerma’s
business development, marketing and distribution efforts at home and abroad to grow interest in
ViaDerma’s patent-pending pharmaceutical delivery system, which allows for rapid transdermal transfer of
active ingredients and immediate relief of symptoms.
Pharmaceutical companies seeking more efficient methods for delivering their products to patients will
have new access to solutions worldwide, as The Brewer Group, Inc. and ViaDerma, Inc. leverage TBG’s
substantial international presence to pave the way for new business alliances and expand the range of
pharmaceuticals delivered using ViaDerma’s technology.
ViaDerma continues to develop new applications for its trade-secret Rapid Active Ingredient Delivery
System (RAIDS), and founder Dr. Christopher Otiko emphasizes its extreme versatility. “The speed of the
RAIDS method for pharmaceutical distribution and the wide variety of products that can utilize it will allow
medical professionals and general consumers alike to benefit from faster treatment,” Dr. Otiko said.
“Products using RAIDS, like the TetraStem broad-spectrum antibiotic, are at the forefront of medical
sophistication—but nearly any drug that medical professionals can administer as a pill can utilize RAIDS for
quicker delivery, from pain relievers to cosmetics. As ViaDerma, Inc. expands abroad, our partnership with
The Brewer Group will combine their experience in international marketing with our revolutionary
technologies to reach ever-larger audiences.”
Using tailored business development strategies including exclusive access to its extensive network and
established relationships spanning the globe, TBG will reach out to synergetic companies, sales and
distribution channels and partner organizations as well as provide ongoing marketing support, help secure
product endorsements and enhance global exposure for ViaDerma’s unique technology.
“I’m excited to be working with an organization like ViaDerma, because the RAIDS system represents a
fundamental shift in the way we should expect treatment to progress,” The Brewer Group CEO H.E.
Ambassador Jack Brewer said. “What if patients saw results from antibiotics after just a day of treatment,
instead of a week? People would come to demand that kind of speed, and TBG is ready to connect ViaDerma
Inc. with pharmaceutical manufacturers to meet those expectations.”
About ViaDerma, Inc.
ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the
pharmaceutical industry through innovative research and development. ViaDerma licenses products in the
fields of medicine ranging from infectious diseases to stem-cell therapy. Dr. Christopher Otiko is the
company’s founder, and ViaDerma became a publicly-traded company in 2014. For more information, go to
www.viadermalicensing.com.
About The Brewer Group, Inc.
Established in 2005, The Brewer Group (“TBG”) is a multi-faceted global investment advisory firm focused on
providing tailored services including investment banking advisory, asset management, specialty finance and
business development for public and private companies as well as high-profile clientele including athletes,
entertainers and world leaders. TBG specializes in multiple sectors including: financial services;
biotechnology & healthcare; sports; media & entertainment; wearable technology & consumer products;
sustainable technology & agriculture; education & cultural exchange; and hospitality. The Brewer Group’s
relationships with high-profile clientele and affiliates including United Nations representatives, global

2. organizations, distribution outlets, governments, key government and non-governmental officials, NPOs,
agencies and unions as well as with various public and private corporations and international organizations
place TBG in a unique position to execute a wide range of services around the globe. Additionally, The
Brewer Group supports a 501(c)(3) non-profit organization, The Jack Brewer Foundation (JBF Worldwide),
which uses its various programs and global initiatives to offer educational opportunities and economic
development to underprivileged individuals around the world and its Chief Executive Officer, Jack Brewer,
also serves as an Ambassador for Peace and Sport for the US Federation of Middle East Peace (USFMEP) at
the United Nations. For further information, please visit www.thebrewergroup.com.
CONTACTS:
Kristi Hofacker
Director of Interactive Marketing & Media
The Brewer Group, Inc.
kristi.hofacker@thebrewergroup.com
651.247.4460
Manny Otiko
ViaDerma, Inc.
mannyotiko@gmail.com
951.842.0783